Terry Hyslop, Ph.D. - Publications

Affiliations: 
2001 Temple University, Philadelphia, PA, United States 
Area:
Statistics, Biostatistics Biology, Pharmacy

156 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Snook AE, Baybutt TR, Xiang B, Abraham TS, Flickinger JC, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Journal For Immunotherapy of Cancer. 7: 104. PMID 31010434 DOI: 10.1186/s40425-019-0576-2  0.48
2018 Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo J, Bibbo M, ... ... Hyslop TM, et al. Loss of nuclear localized Parathyroid Hormone-related Protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed Stat5 signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30097435 DOI: 10.1158/1078-0432.CCR-17-3280  0.52
2018 Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry NL, Tolaney S, Dang CT, Krop I, Harris LN, et al. Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037817 DOI: 10.1158/1078-0432.CCR-17-3431  0.52
2017 Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Research. 77: 5095-5106. PMID 28916678 DOI: 10.1158/0008-5472.CAN-17-0859  0.48
2017 Xu Y, Wang Y, Liu H, Shi Q, Zhu D, Amos CI, Fang S, Lee JE, Hyslop T, Li X, Han J, Wei Q. Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Molecular Carcinogenesis. PMID 28796414 DOI: 10.1002/mc.22716  0.36
2017 Liu S, Wang Y, Xue W, Liu H, Xu Y, Shi Q, Wu W, Zhu D, Amos CI, Fang S, Lee JE, Hyslop T, Li Y, Han J, Wei Q. Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival. International Journal of Cancer. PMID 28510328 DOI: 10.1002/ijc.30785  0.52
2017 Chervoneva I, Freydin B, Hyslop T, Waldman SA. Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Statistical Methods in Medical Research. 962280216683204. PMID 28504051 DOI: 10.1177/0962280216683204  0.52
2016 Snook AE, Baybutt TR, Hyslop T, Waldman SA. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Human Gene Therapy Methods. PMID 27903079 DOI: 10.1089/hgtb.2016.114  0.48
2016 Peck AR, Girondo MA, Liu C, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Freydin B, Hyslop T, Chervoneva I, Rui H. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27312066 DOI: 10.1038/modpathol.2016.112  0.52
2016 Adam MA, Thomas S, Youngwirth L, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes? Annals of Surgery. PMID 26967630 DOI: 10.1097/SLA.0000000000001688  0.52
2016 Hwang ES, Locklear TD, Rushing CN, Samsa G, Abernethy AP, Hyslop T, Atisha DM. Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26951322 DOI: 10.1200/JCO.2015.61.5427  0.52
2016 Lai Y, Wang C, Civan JM, Palazzo JP, Ye Z, Hyslop T, Lin J, Myers RE, Li B, Jiang B, Sama A, Xing J, Yang H. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival from Colon Cancer: A United States Population-Based Study. Gastroenterology. PMID 26836586 DOI: 10.1053/j.gastro.2016.01.030  0.52
2016 Palumbo A, Michael Y, Hyslop T. Latent class model characterization of neighborhood socioeconomic status. Cancer Causes & Control : Ccc. PMID 26797452 DOI: 10.1007/s10552-015-0711-4  0.52
2016 Lin JE, Colon-Gonzalez F, Blomain E, Kim GW, Aing A, Stoecker B, Rock J, Snook AE, Zhan T, Hyslop TM, Tomczak M, Blumberg RS, Waldman SA. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. Cancer Research. 76: 339-346. PMID 26773096 DOI: 10.1158/0008-5472.CAN-15-1467-T  0.52
2015 Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Research and Treatment. PMID 26573830 DOI: 10.1007/s10549-015-3636-4  0.36
2015 He K, Li Y, Zhu J, Liu H, Lee JE, Amos CI, Hyslop T, Jin J, Lin H, Wei Q, Li Y. Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates. Bioinformatics (Oxford, England). PMID 26382192 DOI: 10.1093/bioinformatics/btv517  0.52
2015 Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene. PMID 26096934 DOI: 10.1038/onc.2015.193  0.52
2015 Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26077238 DOI: 10.1200/JCO.2014.59.8391  0.52
2015 Showalter TN, Hegarty SE, Rabinowitz C, Maio V, Hyslop T, Dicker AP, Louis DZ. Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy. International Journal of Radiation Oncology, Biology, Physics. 91: 752-9. PMID 25752388 DOI: 10.1016/j.ijrobp.2014.11.038  0.52
2015 Hegarty SE, Hyslop T, Dicker AP, Showalter TN. Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. Plos One. 10: e0118430. PMID 25706657 DOI: 10.1371/journal.pone.0118430  0.52
2015 Wang C, Civan J, Lai Y, Cristofanilli M, Hyslop T, Palazzo JP, Myers RE, Li B, Ye Z, Zhang K, Xing J, Yang H. Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. Cancer Causes & Control : Ccc. 26: 45-56. PMID 25359303 DOI: 10.1007/s10552-014-0481-4  0.52
2015 Adam MA, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. The Journal of Clinical Endocrinology and Metabolism. 100: 115-21. PMID 25337927 DOI: 10.1210/jc.2014-3039  0.52
2015 Zhang K, Lai Y, Axelrod R, Campling B, Hyslop T, Civan J, Solomides C, Myers RE, Lu B, Bar Ad V, Li B, Ye Z, Yang H. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. International Journal of Cancer. Journal International Du Cancer. 136: 382-91. PMID 24866905 DOI: 10.1002/ijc.28995  0.52
2015 Mishra MV, Scher ED, Andrel J, Margules AC, Hegarty SE, Trabulsi EJ, Hyslop T, Den RB, Lallas CD, Gomella LG, Dicker AP, Showalter TN. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. American Journal of Clinical Oncology. 38: 55-60. PMID 24051934 DOI: 10.1097/COC.0b013e318287bb6b  0.52
2014 Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2328-37. PMID 25304930 DOI: 10.1158/1055-9965.EPI-14-0440  0.52
2014 Lai Y, Palazzo JP, Cristofanilli M, Hyslop T, Civan J, Avery T, Myers RE, Li B, Ye Z, Xing J, Yang H. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. Breast Cancer Research and Treatment. 148: 175-85. PMID 25261294 DOI: 10.1007/s10549-014-3152-y  0.52
2014 Crandley EF, Hegarty SE, Hyslop T, Wilson DD, Dicker AP, Showalter TN. Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy. Cancer Medicine. 3: 397-405. PMID 24519910 DOI: 10.1002/cam4.205  0.52
2014 Dampier C, Ely B, Brodecki D, Coleman C, Aertker L, Sendecki JA, Leiby B, Kesler K, Hyslop T, Stuart M. Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease. Pediatric Blood & Cancer. 61: 291-6. PMID 24115743 DOI: 10.1002/pbc.24796  0.52
2014 Al-Zoubi M, Chipitsyna G, Saxena S, Sarosiek K, Gandhi A, Kang CY, Relles D, Andrelsendecki J, Hyslop T, Yeo CJ, Arafat HA. Overexpressing TNF-alpha in pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and reduces fatty acid synthesis via downregulation of sterol regulatory element binding protein-1 and activation of acetyl CoA carboxylase. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 18: 257-68; discussion 2. PMID 24091913 DOI: 10.1007/s11605-013-2370-7  0.52
2014 Kang CY, Wang J, Axell-House D, Soni P, Chu ML, Chipitsyna G, Sarosiek K, Sendecki J, Hyslop T, Al-Zoubi M, Yeo CJ, Arafat HA. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 18: 7-15. PMID 24002763 DOI: 10.1007/s11605-013-2326-y  0.52
2014 Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene. 33: 2215-24. PMID 23708665 DOI: 10.1038/onc.2013.172  0.52
2013 Yang N, Liu C, Peck AR, Girondo MA, Yanac AF, Tran TH, Utama FE, Tanaka T, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Rui H. Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment. Breast Cancer Research : Bcr. 15: R73. PMID 24004716 DOI: 10.1186/bcr3467  0.52
2013 Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. Journal of Gastrointestinal Cancer. 44: 293-304. PMID 23549858 DOI: 10.1007/s12029-013-9491-9  0.52
2013 Hyslop T, Waldman SA. Molecular staging of node negative patients with colorectal cancer. Journal of Cancer. 4: 193-9. PMID 23459453 DOI: 10.7150/jca.5830  0.52
2013 Hyslop T, Waldman SA. Guanylyl cyclase C as a biomarker in colorectal cancer. Biomarkers in Medicine. 7: 159-67. PMID 23387497 DOI: 10.2217/bmm.12.90  0.52
2013 Hyslop T, Michael Y, Avery T, Rui H. Population and target considerations for triple-negative breast cancer clinical trials. Biomarkers in Medicine. 7: 11-21. PMID 23387481 DOI: 10.2217/bmm.12.114  0.52
2013 Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. Bmc Cancer. 13: 23. PMID 23324165 DOI: 10.1186/1471-2407-13-23  0.52
2013 Relles D, Sendecki J, Chipitsyna G, Hyslop T, Yeo CJ, Arafat HA. Circadian gene expression and clinicopathologic correlates in pancreatic cancer. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 17: 443-50. PMID 23254314 DOI: 10.1007/s11605-012-2112-2  0.52
2013 Carter TI, Fong ZV, Hyslop T, Lavu H, Tan WP, Hardacre J, Sauter PK, Kennedy EP, Yeo CJ, Rosato EL. A dual-institution randomized controlled trial of remnant closure after distal pancreatectomy: does the addition of a falciform patch and fibrin glue improve outcomes? Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 17: 102-9. PMID 22798186 DOI: 10.1007/s11605-012-1963-x  0.52
2013 Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. International Journal of Radiation Oncology, Biology, Physics. 85: 321-8. PMID 22687197 DOI: 10.1016/j.ijrobp.2012.04.017  0.52
2012 Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, ... ... Hyslop T, et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Research : Bcr. 14: R130. PMID 23036105 DOI: 10.1186/bcr3328  0.52
2012 Champ CE, Hegarty SE, Shen X, Mishra MV, Dicker AP, Trabulsi EJ, Lallas CD, Gomella LG, Hyslop T, Showalter TN. Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology. 80: 374-81. PMID 22857759 DOI: 10.1016/j.urology.2012.02.058  0.52
2012 Gong JP, Schulz S, Hyslop T, Waldman SA. GUCY2C molecular staging personalizes colorectal cancer patient management. Biomarkers in Medicine. 6: 339-48. PMID 22731908 DOI: 10.2217/bmm.12.24  0.52
2012 Yang H, Qu F, Myers RE, Bao G, Hyslop T, Hu G, Fei F, Xing J. Genetic variations in stem cell-related genes and colorectal cancer prognosis. Journal of Gastrointestinal Cancer. 43: 584-93. PMID 22528324 DOI: 10.1007/s12029-012-9388-z  0.52
2012 Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. Molecular staging individualizing cancer management. Journal of Surgical Oncology. 105: 468-74. PMID 22441898 DOI: 10.1002/jso.21858  0.52
2012 Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, Garcia AV, Valentino MA, Hyslop T, Schulz S, Waldman SA. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. Plos One. 7: e31686. PMID 22384056 DOI: 10.1371/journal.pone.0031686  0.52
2012 Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. Journal of Surgical Oncology. 106: 24-30. PMID 22252429 DOI: 10.1002/jso.23051  0.52
2012 Shen X, Zaorsky NG, Mishra MV, Foley KA, Hyslop T, Hegarty S, Pizzi LT, Dicker AP, Showalter TN. Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology (London, England). 8: 37-54. PMID 22149034 DOI: 10.2217/fon.11.131  0.52
2012 Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, Solomides C, Peiper SC, Witkiewicz AK. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 118: 3484-93. PMID 22086503 DOI: 10.1002/cncr.26661  0.52
2012 Waldron T, De Dominici M, Soliera AR, Audia A, Iacobucci I, Lonetti A, Martinelli G, Zhang Y, Martinez R, Hyslop T, Bender TP, Calabretta B. c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells. Leukemia. 26: 644-53. PMID 21960247 DOI: 10.1038/leu.2011.264  0.52
2012 Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer. 118: 2532-40. PMID 21887684 DOI: 10.1002/cncr.26516  0.52
2012 Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, Hyslop T, Mastrangelo MJ. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. Journal of Surgical Oncology. 105: 15-20. PMID 21815149 DOI: 10.1002/jso.22051  0.52
2011 Sullivan J, Gong Q, Hyslop T, Lavu H, Chipitsyna G, Yeo CJ, Arafat HA. Serum monocyte chemoattractant protein-1 in pancreatic cancer. Journal of Oncology. 2011: 518394. PMID 21977031 DOI: 10.1155/2011/518394  0.52
2011 Chen ML, Shah VP, Crommelin DJ, Shargel L, Bashaw D, Bhatti M, Blume H, Dressman J, Ducharme M, Fackler P, Hyslop T, Lutter L, Morais J, Ormsby E, Thomas S, et al. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 44: 506-13. PMID 21946259 DOI: 10.1016/j.ejps.2011.09.010  0.52
2011 Grosso D, Carabasi M, Filicko-O'Hara J, Kasner M, Wagner JL, Colombe B, Cornett Farley P, O'Hara W, Flomenberg P, Werner-Wasik M, Brunner J, Mookerjee B, Hyslop T, Weiss M, Flomenberg N. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood. 118: 4732-9. PMID 21868572 DOI: 10.1182/blood-2011-07-365338  0.52
2011 Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. The Journal of Clinical Investigation. 121: 3578-88. PMID 21865642 DOI: 10.1172/JCI57925  0.52
2011 Chen ML, Shah VP, Crommelin DJ, Shargel L, Bashaw D, Bhatti M, Blume H, Dressman J, Ducharme M, Fackler P, Hyslop T, Lutter L, Morais J, Ormsby E, Thomas S, et al. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report. The Aaps Journal. 13: 556-64. PMID 21845486 DOI: 10.1208/s12248-011-9294-5  0.52
2011 Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, Hyslop T, Nevalainen MT, Sauter G, Rui H. Signal transducer and activator of transcription-3 and breast cancer prognosis. American Journal of Cancer Research. 1: 347-55. PMID 21776434  0.32
2011 Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. The American Journal of Pathology. 179: 1171-8. PMID 21756866 DOI: 10.1016/j.ajpath.2011.05.043  0.52
2011 Li X, Chan TO, Myers V, Chowdhury I, Zhang XQ, Song J, Zhang J, Andrel J, Funakoshi H, Robbins J, Koch WJ, Hyslop T, Cheung JY, Feldman AM. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation. 124: 572-81. PMID 21747049 DOI: 10.1161/CIRCULATIONAHA.111.021352  0.52
2011 Wuthrick EJ, Kamrava M, Curran WJ, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, Dicker AP. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer. 117: 5548-59. PMID 21647871 DOI: 10.1002/cncr.26216  0.52
2011 Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2448-58. PMID 21576635 DOI: 10.1200/JCO.2010.30.3552  0.52
2011 Xing J, Myers RE, He X, Qu F, Zhou F, Ma X, Hyslop T, Bao G, Wan S, Yang H, Chen Z. GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. European Journal of Cancer (Oxford, England : 1990). 47: 1699-707. PMID 21402474 DOI: 10.1016/j.ejca.2011.02.004  0.52
2011 Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3293-303. PMID 21307149 DOI: 10.1158/1078-0432.CCR-10-3113  0.52
2011 Siddiqui AA, Sifri R, Hyslop T, Andrel J, Rosenthal M, Vernon SW, Cocroft J, Myers RE. Race and response to colon cancer screening interventions. Preventive Medicine. 52: 262-4. PMID 21256149 DOI: 10.1016/j.ypmed.2011.01.005  0.52
2011 Toll AD, Fabius D, Hyslop T, Pequignot E, DiMarino AJ, Infantolino A, Palazzo JP. Prognostic significance of high-grade dysplasia in colorectal adenomas. Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland. 13: 370-3. PMID 20718835 DOI: 10.1111/j.1463-1318.2010.02385.x  0.52
2011 Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot EC, Freydin BC, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, et al. Reply to A. Italiano Journal of Clinical Oncology. 29: 4718-4719. DOI: 10.1200/JCO.2011.38.5187  0.52
2010 Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. International Journal of Cancer. Journal International Du Cancer. 127: 2949-58. PMID 21351273 DOI: 10.1002/ijc.25498  0.52
2010 Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. Molecular staging estimates occult tumor burden in colorectal cancer. Advances in Clinical Chemistry. 52: 19-39. PMID 21275338 DOI: 10.1016/S0065-2423(10)52007-9  0.52
2010 Liu Z, Magder LS, Hyslop T, Mao L. Survival associated pathway identification with group Lp penalized global AUC maximization. Algorithms For Molecular Biology : Amb. 5: 30. PMID 20712896 DOI: 10.1186/1748-7188-5-30  0.52
2010 Sifri R, Rosenthal M, Hyslop T, Andrel J, Wender R, Vernon SW, Cocroft J, Myers RE. Factors associated with colorectal cancer screening decision stage. Preventive Medicine. 51: 329-31. PMID 20600255 DOI: 10.1016/j.ypmed.2010.06.015  0.52
2010 Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiation Oncology (London, England). 5: 46. PMID 20509969 DOI: 10.1186/1748-717X-5-46  0.52
2010 Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3048-53. PMID 20479391 DOI: 10.1200/JCO.2009.25.6941  0.52
2010 Chervoneva I, Li Y, Schulz S, Croker S, Wilson C, Waldman SA, Hyslop T. Selection of optimal reference genes for normalization in quantitative RT-PCR. Bmc Bioinformatics. 11: 253. PMID 20470420 DOI: 10.1186/1471-2105-11-253  0.52
2010 Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM, Knudsen KE. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Research. 70: 3975-84. PMID 20460515 DOI: 10.1158/0008-5472.CAN-09-3468  0.52
2010 Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocrine-Related Cancer. 17: 481-93. PMID 20233708 DOI: 10.1677/ERC-09-0328  0.52
2010 Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, Bubendorf L, Nevalainen MT. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. The American Journal of Pathology. 176: 1959-72. PMID 20167868 DOI: 10.2353/ajpath.2010.090653  0.52
2010 Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C, Hyslop T, Knudsen KE, Sette C. Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Research. 70: 229-39. PMID 20028857 DOI: 10.1158/0008-5472.CAN-09-2788  0.52
2010 Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 138: 241-54. PMID 19737566 DOI: 10.1053/j.gastro.2009.08.064  0.52
2010 Liu Z, Hyslop T. Partial AUC for differentiated gene detection 10th Ieee International Conference On Bioinformatics and Bioengineering 2010, Bibe 2010. 310-311. DOI: 10.1109/BIBE.2010.68  0.52
2009 Tian L, Zhou J, Casimiro MC, Liang B, Ojeifo JO, Wang M, Hyslop T, Wang C, Pestell RG. Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Research. 69: 9236-44. PMID 19934321 DOI: 10.1158/0008-5472.CAN-09-2067  0.52
2009 Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Review of Molecular Diagnostics. 9: 777-85. PMID 19895223 DOI: 10.1586/erm.09.67  0.52
2009 Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, Ju X, Li Z, Yu Z, Zhou J, Johnson M, Fortina P, Hyslop T, Windle JJ, Pestell RG. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proceedings of the National Academy of Sciences of the United States of America. 106: 19035-9. PMID 19858489 DOI: 10.1073/pnas.0910009106  0.52
2009 Cohn HI, Xi Y, Pesant S, Harris DM, Hyslop T, Falkner B, Eckhart AD. G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension. 54: 71-6. PMID 19487588 DOI: 10.1161/HYPERTENSIONAHA.108.125955  0.52
2009 Berger AC, Howard TJ, Kennedy EP, Sauter PK, Bower-Cherry M, Dutkevitch S, Hyslop T, Schmidt CM, Rosato EL, Lavu H, Nakeeb A, Pitt HA, Lillemoe KD, Yeo CJ. Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. Journal of the American College of Surgeons. 208: 738-47; discussion 7. PMID 19476827 DOI: 10.1016/j.jamcollsurg.2008.12.031  0.52
2009 Showalter TN, Rao AS, Rani Anne P, Rosato FE, Rosato EL, Andrel J, Hyslop T, Xu X, Berger AC. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Annals of Surgical Oncology. 16: 2116-22. PMID 19437078 DOI: 10.1245/s10434-009-0498-1  0.52
2009 Hyslop T, Jung SH. Journal of Biopharmaceutical Statistics. From the editors. Journal of Biopharmaceutical Statistics. 19: 413. PMID 19384684 DOI: 10.1080/10543400902800452  0.52
2009 Levi L, Pekarski I, Gutman E, Fortina P, Hyslop T, Biran J, Levavi-Sivan B, Lubzens E. Revealing genes associated with vitellogenesis in the liver of the zebrafish (Danio rerio) by transcriptome profiling. Bmc Genomics. 10: 141. PMID 19335895 DOI: 10.1186/1471-2164-10-141  0.52
2009 Bednarz G, Machtay M, Werner-Wasik M, Downes B, Bogner J, Hyslop T, Galvin J, Evans J, Curran W, Andrews D. Report on a randomized trial comparing two forms of immobilization of the head for fractionated stereotactic radiotherapy. Medical Physics. 36: 12-7. PMID 19235368 DOI: 10.1118/1.3030950  0.52
2009 Williams TK, Rosato EL, Kennedy EP, Chojnacki KA, Andrel J, Hyslop T, Doria C, Sauter PK, Bloom J, Yeo CJ, Berger AC. Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. Journal of the American College of Surgeons. 208: 210-7. PMID 19228532 DOI: 10.1016/j.jamcollsurg.2008.10.019  0.52
2009 Waldman SA, Hyslop T, Schulz S, Barkun A, Nielsen K, Haaf J, Bonaccorso C, Li Y, Weinberg DS. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. Jama. 301: 745-52. PMID 19224751 DOI: 10.1001/jama.2009.141  0.52
2009 Jimbo M, Myers RE, Meyer B, Hyslop T, Cocroft J, Turner BJ, Weinberg DS. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Annals of Family Medicine. 7: 11-6. PMID 19139444 DOI: 10.1370/afm.906  0.52
2009 Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, Intenzo CM, Keane W. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head & Neck. 31: 195-201. PMID 19107945 DOI: 10.1002/hed.20942  0.52
2008 Hyslop T. Sample size in pilot genetic studies. Clinical and Translational Science. 1: 162. PMID 20443841 DOI: 10.1111/j.1752-8062.2008.00042.x  0.52
2008 Barbarotto E, Secchiero P, Dasgupta A, Fortina P, Calin GA, Hyslop T. MicroRNAs as new players in the genomic galaxy and disease puzzles. Clinical and Translational Science. 1: 50-6. PMID 20443818 DOI: 10.1111/j.1752-8062.2008.00028.x  0.52
2008 Haidar SH, Makhlouf F, Schuirmann DJ, Hyslop T, Davit B, Conner D, Yu LX. Evaluation of a scaling approach for the bioequivalence of highly variable drugs. The Aaps Journal. 10: 450-4. PMID 18726698 DOI: 10.1208/s12248-008-9053-4  0.52
2008 Myers RE, Hyslop T, Sifri R, Bittner-Fagan H, Katurakes NC, Cocroft J, Dicarlo M, Wolf T. Tailored navigation in colorectal cancer screening. Medical Care. 46: S123-31. PMID 18725824 DOI: 10.1097/MLR.0b013e31817fdf46  0.52
2008 Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T, McCue P, Pestell RG. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. The Journal of Cell Biology. 182: 509-17. PMID 18695042 DOI: 10.1083/jcb.200801079  0.52
2007 Chervoneva I, Li Y, Iglewicz B, Waldman S, Hyslop T. Relative quantification based on logistic models for individual polymerase chain reactions. Statistics in Medicine. 26: 5596-611. PMID 17968873 DOI: 10.1002/sim.3127  0.52
2007 Myers RE, Sifri R, Hyslop T, Rosenthal M, Vernon SW, Cocroft J, Wolf T, Andrel J, Wender R. A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer. 110: 2083-91. PMID 17893869 DOI: 10.1002/cncr.23022  0.52
2007 Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 12: 215-29. PMID 17785203 DOI: 10.1016/j.ccr.2007.07.027  0.52
2007 Tang Z, Diamond MA, Chen JM, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purzycki A, Wagner J, McNamara DM, Kukulski T, Wos S, Velazquez EJ, Ardlie K, Feldman AM. Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. Clinical Pharmacology and Therapeutics. 82: 435-40. PMID 17728764 DOI: 10.1038/sj.clpt.6100331  0.52
2007 Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 133: 599-607. PMID 17681179 DOI: 10.1053/j.gastro.2007.05.052  0.52
2007 Sevignani C, Calin GA, Nnadi SC, Shimizu M, Davuluri RV, Hyslop T, Demant P, Croce CM, Siracusa LD. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proceedings of the National Academy of Sciences of the United States of America. 104: 8017-22. PMID 17470785 DOI: 10.1073/pnas.0702177104  0.52
2007 Fortina P, Kricka LJ, Graves DJ, Park J, Hyslop T, Tam F, Halas N, Surrey S, Waldman SA. Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends in Biotechnology. 25: 145-52. PMID 17316852 DOI: 10.1016/j.tibtech.2007.02.005  0.52
2007 Chervoneva I, Hyslop T, Hauck WW. A multivariate test for population bioequivalence. Statistics in Medicine. 26: 1208-23. PMID 16810712 DOI: 10.1002/sim.2605  0.52
2006 Waldman SA, Fortina P, Surrey S, Hyslop T, Kricka LJ, Graves DJ. Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncology (London, England). 2: 705-16. PMID 17155897 DOI: 10.2217/14796694.2.6.705  0.52
2006 Jimbo M, Meyer B, Hyslop T, Cocroft J, Turner BJ, Weinberg DS, Myers RE. Effectiveness of complete diagnostic examination in clinical practice settings. Cancer Detection and Prevention. 30: 545-51. PMID 17113240 DOI: 10.1016/j.cdp.2006.10.001  0.52
2006 Chervoneva I, Iglewicz B, Hyslop T. A general approach for two-stage analysis of multilevel clustered non-Gaussian data. Biometrics. 62: 752-9. PMID 16984317 DOI: 10.1111/j.1541-0420.2005.00512.x  0.52
2006 Goldberg J, Purfield P, Roberts N, Lupinacci P, Fagan M, Hyslop T. The Philadelphia Episiotomy Intervention Study. The Journal of Reproductive Medicine. 51: 603-9. PMID 16967628  0.52
2006 Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4545-52. PMID 16899600 DOI: 10.1158/1078-0432.CCR-06-0865  0.52
2006 Ness A, Baxter J, Hyslop T, Berghella V. Progesterone for preventing premature birth: practice patterns of board-certified maternal-fetal medicine specialists in the United States. The Journal of Reproductive Medicine. 51: 411-5. PMID 16779989  0.52
2006 Chervoneva I, Hyslop T, Iglewicz B, Johns L, Wolfe HR, Schulz S, Leong E, Waldman S. Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry. 348: 198-208. PMID 16336939 DOI: 10.1016/j.ab.2005.10.042  0.52
2005 Tiro JA, Vernon SW, Hyslop T, Myers RE. Factorial validity and invariance of a survey measuring psychosocial correlates of colorectal cancer screening among African Americans and Caucasians. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 2855-61. PMID 16365000 DOI: 10.1158/1055-9965.EPI-05-0217  0.52
2005 Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8549-56. PMID 16361536 DOI: 10.1158/1078-0432.CCR-05-1624  0.52
2005 Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Review of Molecular Diagnostics. 5: 701-13. PMID 16149873 DOI: 10.1586/14737159.5.5.701  0.52
2004 Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 100: 2317-27. PMID 15160334 DOI: 10.1002/cncr.20260  0.52
2004 Myers RE, Turner B, Weinberg D, Hyslop T, Hauck WW, Brigham T, Rothermel T, Grana J, Schlackman N. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Preventive Medicine. 38: 375-81. PMID 15020170 DOI: 10.1016/j.ypmed.2003.11.010  0.52
2004 Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America. 101: 2999-3004. PMID 14973191 DOI: 10.1073/pnas.0307323101  0.52
2003 Sifri R, Myers R, Hyslop T, Turner B, Cocroft J, Rothermel T, Grana J, Schlackman N. Use of cancer susceptibility testing among primary care physicians Clinical Genetics. 64: 355-360. PMID 12974741 DOI: 10.1034/j.1399-0004.2003.00131.x  0.52
2003 Lin CC, Kenyon L, Hyslop T, Hammond E, Andrews DW, Curran WJ, Dicker AP. Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. American Journal of Clinical Oncology. 26: S98-102. PMID 12902865 DOI: 10.1097/01.COC.0000074308.97198.D0  0.52
2003 Bloomer CW, Kenyon L, Hammond E, Hyslop T, Andrews DW, Curran WJ, Dicker AP. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas. American Journal of Clinical Oncology. 26: S75-80. PMID 12902861 DOI: 10.1097/01.COC.0000074163.69381.22  0.52
2003 Turner B, Myers RE, Hyslop T, Hauck WW, Weinberg D, Brigham T, Grana J, Rothermel T, Schlackman N. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. Journal of General Internal Medicine. 18: 357-63. PMID 12795734 DOI: 10.1046/j.1525-1497.2003.20525.x  0.52
2003 Ober C, Aldrich CL, Chervoneva I, Billstrand C, Rahimov F, Gray HL, Hyslop T. Variation in the HLA-G promoter region influences miscarriage rates. American Journal of Human Genetics. 72: 1425-35. PMID 12721954 DOI: 10.1086/375501  0.52
2003 Goldberg J, Hyslop T, Tolosa JE, Sultana C. Racial differences in severe perineal lacerations after vaginal delivery American Journal of Obstetrics and Gynecology. 188: 1063-1067. PMID 12712111 DOI: 10.1067/mob.2003.251  0.52
2003 Hyslop T, Lupinacci PJ. A nonparametric fitted test for the Behrens-Fisher problem Journal of Modern Applied Statistical Methods. 2: 414-424.  0.52
2002 Herrine SK, Michael B, Ma WL, Rossi S, Dunn SR, Hyslop T. Development of an HCV infection risk stratification algorithm for patients on chronic hemodialysis. The American Journal of Gastroenterology. 97: 2619-22. PMID 12385449 DOI: 10.1111/j.1572-0241.2002.06039.x  0.52
2002 Berghella V, Haas S, Chervoneva I, Hyslop T. Patients with prior second-trimester loss: prophylactic cerclage or serial transvaginal sonograms? American Journal of Obstetrics and Gynecology. 187: 747-51. PMID 12237658 DOI: 10.1067/mob.2002.124289  0.52
2002 Goldberg J, Holtz D, Hyslop T, Tolosa JE. Has the use of routine episiotomy decreased? Examination of episiotomy rates from 1983 to 2000 Obstetrics and Gynecology. 99: 395-400. PMID 11864665 DOI: 10.1016/S0029-7844(01)01756-2  0.52
2001 Reddy UM, Shah SS, Nemiroff RL, Ballas SK, Hyslop T, Chen J, Wapner RJ, Sciscione AC. In vitro sealing of punctured fetal membranes: Potential treatment for midtrimester premature rupture of membranes American Journal of Obstetrics and Gynecology. 185: 1090-1093. PMID 11717639 DOI: 10.1067/mob.2001.117685  0.52
2001 Myers RE, Turner B, Weinberg D, Hauck WW, Hyslop T, Brigham T, Rothermel T, Grana J, Schlackman N. Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Preventive Medicine. 33: 249-60. PMID 11570828 DOI: 10.1006/pmed.2001.0878  0.52
2001 Myers RE, Fishbein G, Hyslop T, Hauck WW, Kutch M, Grana JR, Schlackman N. Measuring complete diagnostic evaluation in colorectal cancer screening Cancer Detection and Prevention. 25: 174-182. PMID 11341353  0.52
2000 Myers RE, Hyslop T, Jennings-Dozier K, Wolf TA, Burgh DY, Diehl JA, Lerman C, Chodak GW. Intention to be tested for prostate cancer risk among african-american men Cancer Epidemiology Biomarkers and Prevention. 9: 1323-1328. PMID 11142417  0.52
2000 Reddy UM, DiVito MM, Armstrong JC, Hyslop T, Wapner RJ. Population adjustment of the definition of the vaginal birth after cesarean rate American Journal of Obstetrics and Gynecology. 183: 1166-1169. PMID 11084560 DOI: 10.1067/mob.2000.109050  0.52
2000 Hyslop T, Hsuan F, Holder DJ. A small sample confidence interval approach to assess individual bioequivalence Statistics in Medicine. 19: 2885-2897. PMID 11033583 DOI: 10.1002/1097-0258(20001030)19:20<2885::AID-SIM553>3.0.CO;2-H  0.52
2000 Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalence criterion: Regulatory considerations Statistics in Medicine. 19: 2821-2842. PMID 11033578 DOI: 10.1002/1097-0258(20001030)19:20<2821::AID-SIM548>3.0.CO;2-L  0.52
2000 Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, Capuzzi D, Kovatich AJ. Overexpression of p21(WAF1-CIP1) and MDM2 characterizes serous borderline ovarian tumors Human Pathology. 31: 698-704. PMID 10872663  0.52
2000 Hauck WW, Hyslop T, Chen ML, Patnaik R, Williams RL, Conner D, Lesko LJ, Machado S, Schuirmann D. Subject-by-formulation interaction in bioequivalence: Conceptual and statistical issues Pharmaceutical Research. 17: 375-380. PMID 10870978 DOI: 10.1023/A:1007508516231  0.52
2000 Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: Risk factors and outcomes for patients with synchronous and metachronous disease Cancer. 88: 2739-2750. PMID 10870056 DOI: 10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J  0.52
2000 Myers RE, Hyslop T, Wolf TA, Burgh D, Kunkel EJS, Oyesanmi OA, Chodak GJ. African-American men and intention to adhere to recommended follow-up for an abnormal prostate cancer early detection examination result Urology. 55: 716-720. PMID 10792087  0.52
2000 Hauck WW, Hyslop T, Anderson S. Generalized treatment effects for clinical trials Statistics in Medicine. 19: 887-899. PMID 10750057  0.52
2000 DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ, Iliakis G. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Research. 60: 1245-53. PMID 10728683  0.52
1999 Myers RE, Hyslop T, Gerrity M, Schlackman N, Hanchak N, Grana J, Turner BJ, Weinberg D, Hauck WW. Physician intention to recommend complete diagnostic evaluation in colorectal cancer screening Cancer Epidemiology Biomarkers and Prevention. 8: 587-593. PMID 10428195  0.52
1999 Ober C, Hyslop T, Hauck WW. Inbreeding effects on fertility in humans: evidence for reproductive compensation. American Journal of Human Genetics. 64: 225-31. PMID 9915962 DOI: 10.1086/302198  0.52
1999 Silverberg SG, Palazzo JP, Hyslop T, Moinfar F. Misconception about mammary intraepithelial neoplasia (MIN) (multiple letters) Breast Journal. 5: 73-77. DOI: 10.1046/j.1524-4741.1999.005001073.x  0.36
1998 Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L. Stage T3 prostate cancer: A nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy Urology. 51: 782-787. PMID 9610592 DOI: 10.1016/S0090-4295(98)00022-3  0.52
1998 Ober C, Hyslop T, Elias S, Weitkamp LR, Hauck WW. Human leukocyte antigen matching and fetal loss: Results of a 10 year prospective study Human Reproduction. 13: 33-38. PMID 9512225 DOI: 10.1093/humrep/13.1.33  0.52
1998 Palazzo JP, Hyslop T. Hyperplastic ductal and lobular lesions and carcinomas in situ of the breast: Reproducibility of current diagnostic criteria among community- and academic-based pathologists Breast Journal. 4: 230-237.  0.52
1997 Werner-Wasik M, Whittington R, Malkowicz SB, Corn BW, Arger P, Reisinger S, Langlotz C, Alexander A, D'Amico AV, Hyslop T, Gomella L, Brownstein K, Wein AJ. Prostate imaging may not be necessary in nonpalpable carcinoma of the prostate Urology. 50: 385-389. PMID 9301702 DOI: 10.1016/S0090-4295(97)00225-2  0.52
1997 Rudoler SB, Corn BW, Shields CL, De Potter P, Hyslop T, Shields JA, Curran WJ. External beam irradiation for choroid metastases: identification of factors predisposing to long-term sequelae. International Journal of Radiation Oncology, Biology, Physics. 38: 251-6. PMID 9226310 DOI: 10.1016/S0360-3016(97)00050-3  0.52
1997 Corn BW, Donahue BR, Rosenstock JG, Hyslop T, Brandon AH, Hegde HH, Cooper JS, Sherr DL, Fisher SA, Berson A, Han H, Abdel-Wahab M, Koprowski CD, Ruffer JE, Curran WJ. Performance status and age as independent predictors of survival among AIDS patients with primary CNS lymphoma: a multivariate analysis of a multi-institutional experience. The Cancer Journal From Scientific American. 3: 52-6. PMID 9072309  0.52
1997 Rudoler SB, Shields CL, Corn BW, De Potter P, Hyslop T, Curran WJ, Shields JA. Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: a multivariate analysis of 188 patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1244-51. PMID 9060569  0.52
1997 Hauck WW, Bois FY, Hyslop T, Gee L, Anderson S. A parametric approach to population bioequivalence Statistics in Medicine. 16: 441-454. PMID 9044531 DOI: 10.1002/(SICI)1097-0258(19970228)16:4<441::AID-SIM390>3.0.CO;2-F  0.52
1996 Hauck WW, Chen ML, Hyslop T, Patnaik R, Schuirmann D, Williams R. Mean difference vs. variability reduction: Tradeoffs in aggregate measures for individual bioequivalence International Journal of Clinical Pharmacology and Therapeutics. 34: 535-541. PMID 8996848  0.52
1996 Gomella LG, Liberman SN, Mulholland SG, Petersen RO, Hyslop T, Corn BW. Induction androgen deprivation plus prostatectomy for stage T3 disease: Failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial Urology. 47: 870-877. PMID 8677579 DOI: 10.1016/S0090-4295(96)00041-6  0.52
1995 Hauck WW, Hyslop T, Anderson S, Bois FY, Tozer TN. Statistical and regulatory considerations for multiple measures in bioequivalence testing Clinical Research and Regulatory Affairs. 12: 249-265. DOI: 10.3109/10601339509019618  0.52
Show low-probability matches.